Sandoz has agreed to acquire Just-Evotec Biologics EU SAS for approximately USD 350 million, enhancing its biosimilar development and manufacturing capabilities to capitalize on a projected USD 300 billion market opportunity over the next decade.

Information on the Target

Sandoz, a global leader in affordable medicines, has announced the acquisition of Just-Evotec Biologics EU SAS (JEB SAS), which includes the Toulouse manufacturing site. This strategic acquisition is intended to enhance Sandoz's capabilities in the development and manufacturing of biosimilars, utilizing innovative continuous manufacturing technology. By owning JEB SAS, Sandoz aims to better position itself to capture a projected market opportunity worth approximately USD 300 billion in the biosimilar sector over the next decade.

The transaction involves an upfront cash payment of approximately USD 350 million for JEB SAS, along with a license for the continuous manufacturing technology that covers an unlimited number of molecules and includes potential royalties for up to 10 specific molecules. This reconfigured approach aligns the financial incentives between Sandoz and Evotec SE, replacing previous contractual commitments with a model focusing on technology licensing and success-based milestones.

Industry Overview

The biosimilars market is experiencing robust growth, driven by increasing demand for affordable biologic therapies. Over the next ten years, the market is projected to reach about USD 300 billion as patents for several major biolog